ArticleHypertension (Dallas, Tex. : 1979)2021
CRISPR/Cas9 Mediated Deletion of the Angiotensinogen Gene Reduces Hypertension: A Potential for Cure?
Article in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- The Research Progress in Targeted Therapy for Hypertension via Heat Shock Proteins.International journal of molecular sciences · 2026Review
- Blood Levels of Angiotensinogen and Risk of Ischemic Stroke: The Multi-Ethnic Study of Atherosclerosis.Journal of the American Heart Association · 2026Observational
- Gene Therapy for Cardiovascular and Cerebrovascular Disease: Mechanisms, Translational Barriers, and the Road Ahead.Biomedicines · 2026Review
- TACO1 regulates mitochondrial adaptation in hypertension-induced cardiac remodeling and heart failure.Research square · 2026Article
- Cardiovascular Science, Medicine, and Society: The Brave New World: The ACC Braunwald Lecture 2025.Journal of the American College of Cardiology · 2026Review
- TGF-β: The Molecular Mechanisms of Atherosclerosis - insights into SMAD Pathways and Gene Therapy Prospects.Current medicinal chemistry · 2026Review
- A comprehensive narrative review on precision medicine approach to hypertension: exploring the role of genetics, epigenetics, microbiome, and artificial intelligence.Journal of health, population, and nutrition · 2025Review
- Review
- Review
- Emerging RNAi Therapies to Treat Hypertension.Molecular diagnosis & therapy · 2025Review
- Harnessing the power of genomics in hypertension: tip of the iceberg?Cambridge prisms. Precision medicine · 2025Review
- Emerging therapeutic frontiers in hypertension management.Frontiers in cardiovascular medicine · 2025Review
- Gene editing of angiotensin for blood pressure management.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes.Arteriosclerosis, thrombosis, and vascular biology · 2023Article
- Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes.bioRxiv : the preprint server for biology · 2023Article
- Basic Principles and Clinical Applications of CRISPR-Based Genome Editing.Yonsei medical journal · 2022Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
[Figure: see text].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.